Diagnosed with Cancer? Your two greatest challenges are understanding cancer and understanding possible side effects from chemo and radiation. Knowledge is Power!
Learn about conventional, complementary, and integrative therapies.
Dealing with treatment side effects? Learn about evidence-based therapies to alleviate your symptoms.
Click the orange button to the right to learn more.
- You are here:
- Home »
- Blog »
- Lung Cancer »
- Enhance Nivolumab in Lung Cancer
Enhance Nivolumab in Lung Cancer
How can you enhance nivolumab in lung cancer? Although no diet can guarantee the efficacy of Nivolumab in NSCLC patients, the research linked and excerpted below suggests that the gut microbiome may enhance Nivolumab efficacy.
The role of gut microbiome on immunotherapy outcomes in lung cancer
Below is a 7-day nivolumab-supportive meal plan designed for patients with non-small cell lung cancer receiving PD-1 immunotherapy. It emphasizes:
-
High fiber (microbiome diversity → better checkpoint response signals)
-
Fermented foods (from foods, not supplements)
-
Polyphenol-rich plants
-
Adequate protein (immune + muscle preservation)
-
Omega-3 fats
-
Low ultra-processed food load
-
Stable glucose pattern
It follows a Mediterranean-microbiome hybrid pattern that aligns best with current immunotherapy–nutrition research.
If appetite, GI tolerance, or weight status differs, I can tune this after.
🗓️ 7-Day Nivolumab-Supportive Meal Plan
Fiber target: ~30–40 g/day
Protein target: ~1.2–1.5 g/kg/day
Fermented foods: 1–2 servings/day
Plant diversity goal: 30+ plant foods/week
Day 1
Breakfast
-
Steel-cut oats
-
Blueberries + ground flaxseed
-
Plain kefir
-
Green tea
Lunch
-
Lentil vegetable soup
-
Mixed greens, olive oil + lemon
-
Whole-grain sourdough slice
-
Sauerkraut side
Snack
-
Apple + walnuts
Dinner
-
Baked salmon
-
Roasted Brussels sprouts + carrots
-
Barley
-
Olive oil drizzle
Day 2
Breakfast
-
Greek yogurt (live cultures)
-
Chia seeds
-
Raspberries
-
Pumpkin seeds
Lunch
-
Chickpea quinoa bowl
-
Spinach, cucumber, tomato, herbs
-
Olive oil + tahini dressing
-
Kimchi side
Snack
-
Pear + almond butter
Dinner
-
Grilled chicken thigh or tofu
-
Sweet potato
-
Broccoli with garlic + olive oil
-
Small miso soup
Day 3
Breakfast
-
Vegetable omelet (onion, mushrooms, spinach)
-
Whole grain toast
-
Avocado
-
Green tea
Lunch
-
Black bean + brown rice bowl
-
Cabbage slaw
-
Salsa + cilantro
-
Yogurt with live cultures
Snack
-
Mixed berries + dark chocolate (70%+)
Dinner
-
Sardines or mackerel
-
Farro salad with herbs + olive oil
-
Roasted zucchini + eggplant
Day 4
Breakfast
-
Overnight oats with kefir
-
Chopped apple
-
Cinnamon
-
Chia seeds
Lunch
-
Split pea soup
-
Arugula salad with walnuts + olive oil
-
Fermented pickles
Snack
-
Carrots + hummus
Dinner
-
Turkey or tempeh stir-fry
-
Mixed vegetables (bok choy, peppers, mushrooms)
-
Brown rice
-
Sesame + olive oil blend
Day 5
Breakfast
-
Smoothie: kefir, spinach, frozen berries, flaxseed, oats
Lunch
-
Mediterranean lentil salad
-
Tomato, parsley, cucumber
-
Olive oil + lemon
-
Whole-grain pita
-
Sauerkraut side
Snack
-
Orange + pistachios
Dinner
-
Baked trout or salmon
-
Roasted cauliflower
-
Quinoa
-
Turmeric + black pepper seasoning
Day 6
Breakfast
-
Greek yogurt
-
Granola (low sugar, whole grain)
-
Pomegranate seeds
-
Sunflower seeds
Lunch
-
White bean + vegetable stew
-
Kale salad with olive oil
-
Kimchi side
Snack
-
Apple + peanut butter
Dinner
-
Grass-fed lean beef or lentil loaf
-
Roasted root vegetables
-
Barley or oat groats
Day 7
Breakfast
-
Oat bran porridge
-
Blackberries
-
Chopped walnuts
-
Green tea
Lunch
-
Quinoa tabbouleh bowl
-
Chickpeas
-
Herbs + olive oil
-
Yogurt with live cultures
Snack
-
Kiwi + almonds
Dinner
-
Baked cod or tofu
-
Brussels sprouts
-
Sweet potato
-
Miso broth
🧬 Weekly Microbiome Boosters Included
-
≥10 legume servings
-
≥5 fermented food servings
-
≥4 fatty fish servings
-
≥30 plant types
-
Daily prebiotic fibers
-
Resistant starch sources (oats, barley, legumes, cooled grains)
⚠️ Adjust If These Occur During Nivolumab
Immune-related colitis or diarrhea
Temporarily reduce:
-
Raw vegetables
-
Very high fiber loads
-
Fermented foods
-
Beans/lentils
Use:
-
Cooked vegetables
-
Oats, rice, bananas
-
Yogurt/kefir only if tolerated
Poor appetite
Use:
-
Smoothies
-
Soups
-
Nut butters
-
Olive oil additions
-
Smaller frequent meals
I am a long-term survivor of an incurable blood cancer called multiple myeloma. In my experience, conventional, FDA-approved cancer therapies can be enhanced with evidence-based non-conventional therapies like diet, exercise and lifestyle.
Please scroll down the page, post a question or comment, and I will reply to you ASAP.
Good luck,
David Emerson
- Cancer Survivor
- Cancer Coach
- Director PeopleBeatingCancer
Changes of microbiome profile during nivolumab treatment in NSCLC patients.
Abstract
Background: Immune Checkpoint Inhibitors (ICIs) are improving the survival of cancer patients, however only the 20-30% of treated patients present long term benefits. Hence in the context of multiple treatment possibilities, the identification of predictive markers of response and toxicity is a challenging approach for drug selection in order to obtain the best clinical benefit. The changes occurring in the microbiota composition has been proposed as a mechanism potentially influencing the response and the toxicity to immunotherapy
Methods: The microbiome composition was studied in an age-matched control-case study of 11 patients affected by non-small cell lung cancer (NSCLC) treated with Nivolumab versus 11 healthy controls (CTRLs). The stool samples of NSCLC patients were collected at cycle 1, 3 and 5.
The microbiome analysis was performed by targeted-metagenomics of the 16S rRNA locus (V3-V4 region) on an Illumina MiSeq Platform. Non-parametrical statistical analyses were performed to assess microbial OTUs distribution and a- and b-diversity indexes were computed to describe the microbial ecology
Results:Microbiota meta-taxonomy was described for the NSCLC patients versus CTRLs and at each time-course of the Nivolumab treatment (C1-C5).
In NSCLC patients Rikenellaceae, Prevotella, Streptococcus, Lactobacillus (p < 0.05), Bacteroides plebeius, Oscillospira, Enterobacteriaceae (p < 0.05) appeared increased compared to CTRLs. Not responders had Ruminococcus bromii, Dialister, Sutterella more abundant than responder patients to therapy (p < 0.05).
Slightly increased in responders appeared Akkermansia muciniphila, Bifidobacterium longum and Faecalibacterium prausnitzii (p < 0.05). Propionibacterium acnes, Veillonella, Staphylococcus aureus, Peptostreptococcus appeared significantly over-expressed, while Clostridium perfringens was significantly reduced at the C1 compared to the C3 time-point of the treatment.
Conclusions: Nivolumab seems to influence the microbiome composition during treatment. Moreover our data confirm significant role of specific gut microbiota bacteria in influencing cancer development and response to immunotherapy.
enhance nivolumab in lung cancer enhance nivolumab in lung cancer